At long last, Sanofi (SNY +1.4%) and Genzyme (GENZ +1.3%) have a deal. Sanofi will pay $74/share...


At long last, Sanofi (SNY +1.4%) and Genzyme (GENZ +1.3%) have a deal. Sanofi will pay $74/share in cash plus a CVR worth as much as $14/share depending on the performance of certain Genzyme drugs. Worth at least $20.1B, it's the second-largest deal in biotech history. (PR)

From other sites
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs